(Q28202517)

1

0 references

Werner Poewe

4

0 references

Christopher G. Goetz

2

object named as

Christopher Goetz

0 references

William C. Koller

Primate models of movement disorders of basal ganglia origin

3

object named as

William Koller

0 references

language of work or name

English

0 references

publication date

4 May 2002

0 references

published in

The Lancet

0 references

volume

359

0 references

issue

9317

0 references

page(s)

1589-98

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Surgery for Parkinson disease: A critical evaluation of the state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Cell replacement strategies for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Drug treatment effects on disease progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

1 reference

7 January 2021

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Multicentre European study of thalamic stimulation in parkinsonian and essential tremor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Sleep attacks and Parkinson's disease treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A Population-Based Investigation of Parkinson's Disease With and Without Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Moclobemide and selegeline in the treatment of depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Prevalence of orthostatic hypotension in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

A controlled study with Dihydergot on patients with orthostatic dysregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908520-3

7 January 2021

10.1016/S0140-6736(02)08520-3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

12047983

1 reference

Consolidated OpenCitations Corpus – April 2017